Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 1, 2007, Pages 117-125

  Azoubel, M C F ^a   Menezes, A M A ^a   Bezerra, D ^a   Oria R B ^a   Ribeiro, R A ^a   Brito, Gerly A C ^a  

^a Federal University of Ceará   (Brazil)

Author keywords

Alveolar bone loss; Cyclooxygenase inhibitors; Etoricoxib; Indomethacin; Inflammation; Periodontitis

Indexed keywords

COLLAGEN FIBER; ETORICOXIB; INDOMETACIN; SODIUM CHLORIDE;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CEMENTUM; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HYPEREMIA; INFLAMMATORY CELL; INTESTINE MUCOSA; MOLAR TOOTH; MORTALITY; NONHUMAN; OSTEOLYSIS; PERIODONTITIS; PERIODONTIUM; PETECHIA; RAT; STOMACH MUCOSA; SURVIVAL RATE; WEIGHT REDUCTION; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 33846311430     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2007000100015     Document Type: Article

References (40)

1. Williams RC. Periodontal disease. N Engl J Med 1990; 322: 373-382.
2. Williams RC, Paquette DW. Understanding the pathogenesis of periodontitis: a century of discovery. J Int Acad Periodontol 2000; 2: 59-63.
3. Ximenez-Fyvie LA, Haffajee AD, Socransky SS. Comparison of the microbiota of supra- and subgingival plaque in health and periodontitis. J Clin Periodontol 2000; 27: 648-657.
4. Ximenez-Fyvie LA, Haffajee AD, Socransky SS. Microbial composition of supra- and subgingival plaque in subjects with adult periodontitis. J Clin Periodontol 2000; 27: 722-732.
5. Page RC. The etiology and pathogenesis of periodontitis. Compend Contin Educ Dent 2002; 23: 11-14.
6. Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol 1993; 64: 432-444.
7. Paquette DW, Williams RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontology 2000; 24: 239-252.
8. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-13931.
9. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997; 53: 563-582.
10. Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res 2000; 2: 379-385.
11. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998; 47 (Suppl 2): S78-S87.
12. Lohinai Z, Stachlewitz R, Szekely AD, Feher E, Dezsi L, Szabo C. Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis. Life Sci 2001; 70: 279-290.
13. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423-433.
14. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996; 35 (Suppl 1): 4-12.
15. Savage R. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? Drugs Aging 2005; 22: 185-200.
16. Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today 2004; 40: 395-414.
17. Bezerra MM, de Lima V, Alencar VB, Vieira IB, Brito GA, Ribeiro RA, et al. Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 2000; 71: 1009-1014.
18. Holzhausen M, Spolidorio DM, Muscara MN, Hebling J, Spolidorio LC. Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats. J Periodontal Res 2005; 40: 208-211.
19. Sallay K, Sanavi F, Ring I, Pham P, Behling UH, Nowotny A. Alveolar bone destruction in the immunosuppressed rat. J Periodontal Res 1982; 17: 263-274.
20. Samejima Y, Ebisu S, Okada H. Effect of infection with Eikenella corrodens on the progression of ligature-induced periodontitis in rats. J Periodontal Res 1990; 25: 308-315.
21. Banerjee AK, Peters TJ. Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. Gut 1990; 31: 1358-1364.
22. Crawford JM, Taubman MA, Smith DJ. The natural history of peridontal bone loss in germfree and gnotobiotic rats infected with periodontopathic microorganisms. J Periodontal Res 1978; 13: 316-325.
23. Bjornsson MJ, Velschow S, Stoltze K, Havemose-Poulsen A, Schou S, Holmstrup P. The influence of diet consistence, drinking water and bedding an periodontal disease in Sprague-Dawley rats. J Periodontal Res 2003; 38: 543-550.
24. Leitao RF, Ribeiro RA, Chaves HV, Rocha FA, Lima V, Brito GA. Nitric oxide synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats. J Periodontol 2005; 76: 956-963.
25. Szabo S, Trier JS, Brown A, Schnoor J, Homan HD, Bradford JC. A quantitative method for assessing the extent of experimental gastric erosions and ulcers. J Pharmacol Methods 1985; 13: 59-66.
26. Trevethick MA, Clayton NM, Strong P, Harman IW. Do infiltrating neutrophils contribute to the pathogenesis of indomethacin induced ulceration of the rat gastric antrum? Gut 1993; 34: 156-160.
27. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, et al. Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998; 124: 1385-1394.
28. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558-566.
29. Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39: 854-862.
30. Zubery Y, Dunstan CR, Story BM, Kesavalu L, Ebersole JL, Holt SC, et al. Bone resorption caused by three periodontal pathogens in vivo in mice is mediated in part by prostaglandin. Infect Immun 1998; 66: 4158-4162.
31. Miyauchi M, Hiraoka M, Oka H, Sato S, Kudo Y, Ogawa I, et al. Immuno-localization of COX-1 and COX-2 in the rat molar periodontal tissue after topical application of lipopolysaccharide. Arch Oral Biol 2004; 49: 739-746.
32. Carter-Bartlett P, Dersot JM, Saffar JL. Periodontal and femoral bone status in periodontitis-affected hamsters receiving a high dose indomethacin treatment. J Biol Buccale 1989; 17: 93-101.
33. Nygard G, Anthony A, Piasecki C, Trevethick MA, Hudson M, Dhillon AP, et al. Acute indomethacin-induced jejunal injury in the rat: early morphological and biochemical changes. Gastroenterology 1994; 106: 567-575.
34. Lugea A, Antolin M, Mourelle M, Guamer F, Malagelada JR. Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs. Gastroenterology 1997; 112: 1931-1939.
35. Chmaisse HM, Antoon JS, Kvietys PR, Grisham MB, Perry MA. Role of leukocytes in indomethacin-induced small bowel injury in the rat. Am J Physiol 1994; 266: G239-G246.
36. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002; 300: 754-761.
37. Laudanno OM, Cesolari JA, Esnarriaga J, Rista L, Piombo G, Maglione C, et al. Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci 2001; 46: 779-784.
38. Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci 2005; 50 (Suppl 1): S16-S23.
39. Scheiman JM. Gastroduodenal safety of cyclooxygenase-2 inhibitors. Curr Pharm Des 2003; 9: 2197-2206.
40. Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J 2005; 118: U1684.